Please login to the form below

Not currently logged in
Email:
Password:

pomalidomide

This page shows the latest pomalidomide news and features for those working in and with pharma, biotech and healthcare.

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

inhibitor. It was cleared for use in combination with pomalidomide and dexamethasone (pom-dex), a standard regimen for the treatment of myeloma.

Latest news

More from news
Approximately 6 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of new Celgene brands like blood cancer therapies Revlimid (lenalidomide) and Pomalyst (pomalidomide)

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....